Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
CNY 63.09
(-3.68%)
CNY 63.09
(-3.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 156.57 Million CNY | 36.87% |
| 2022 | 398.98 Million CNY | 143.68% |
| 2021 | 163.73 Million CNY | 51.49% |
| 2020 | 108.07 Million CNY | 63.53% |
| 2019 | 66.09 Million CNY | 29.7% |
| 2018 | 50.95 Million CNY | 22.16% |
| 2017 | 41.71 Million CNY | 44.44% |
| 2016 | 28.87 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 50.18 Million CNY | -11.92% |
| 2024 Q1 | 48.71 Million CNY | -57.73% |
| 2024 Q2 | 47.4 Million CNY | -2.7% |
| 2023 Q3 | 59.16 Million CNY | 21.11% |
| 2023 FY | 546.08 Million CNY | 36.87% |
| 2023 Q4 | 115.24 Million CNY | 94.8% |
| 2023 Q2 | 48.85 Million CNY | -32.14% |
| 2023 Q1 | 71.98 Million CNY | 51.49% |
| 2022 FY | 398.98 Million CNY | 143.68% |
| 2022 Q3 | 130.87 Million CNY | 15.79% |
| 2022 Q2 | 113.02 Million CNY | 5.07% |
| 2022 Q1 | 107.56 Million CNY | 207.99% |
| 2022 Q4 | 47.51 Million CNY | -63.69% |
| 2021 Q1 | 32.64 Million CNY | -25.27% |
| 2021 Q4 | 34.92 Million CNY | -40.97% |
| 2021 Q3 | 59.16 Million CNY | 59.97% |
| 2021 Q2 | 36.98 Million CNY | 13.29% |
| 2021 FY | 163.73 Million CNY | 51.49% |
| 2020 Q4 | 43.68 Million CNY | 111.56% |
| 2020 Q3 | 20.65 Million CNY | -31.36% |
| 2020 Q2 | 30.08 Million CNY | 120.32% |
| 2020 Q1 | 13.65 Million CNY | -36.88% |
| 2020 FY | 108.07 Million CNY | 63.53% |
| 2019 Q4 | 21.63 Million CNY | 0.0% |
| 2019 FY | 66.09 Million CNY | 29.7% |
| 2018 FY | 50.95 Million CNY | 22.16% |
| 2017 FY | 41.71 Million CNY | 44.44% |
| 2016 FY | 28.87 Million CNY | 0.0% |